Qiagen Stock Price, Forecast & Analysis (NYSE:QGEN)

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Qiagen NV (NYSE:QGEN) posted its quarterly earnings results on Wednesday, October, 30th. The company reported $0.36 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.35 by $0.01. The business had revenue of $382.70 million for the quarter, compared to analysts' expectations of $382.98 million. Qiagen had a negative net margin of 1.68% and a positive return on equity of 12.24%. The business's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.35 EPS. View Qiagen's Earnings History.

Qiagen is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Qiagen.

Qiagen issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of $1.43-1.44 for the period, compared to the Thomson Reuters consensus estimate of $1.38. The company issued revenue guidance of ~$1.56 billion, compared to the consensus revenue estimate of $1.53 billion.

16 analysts have issued 12 month price objectives for Qiagen's stock. Their forecasts range from $31.00 to $42.00. On average, they anticipate Qiagen's stock price to reach $36.33 in the next twelve months. This suggests that the stock has a possible downside of 3.1%. View Analyst Price Targets for Qiagen.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen.

Media headlines about QGEN stock have been trending somewhat negative on Friday, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Qiagen earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Qiagen.

Qiagen saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,010,000 shares, an increase of 13.3% from the September 15th total of 3,540,000 shares. Based on an average trading volume of 1,390,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 1.9% of the shares of the company are short sold. View Qiagen's Current Options Chain.

Some companies that are related to Qiagen include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), bluebird bio (BLUE), BioNTech (BNTX), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO) and Crispr Therapeutics (CRSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Netflix (NFLX), Gilead Sciences (GILD), Exelixis (EXEL), NVIDIA (NVDA), Twitter (TWTR), Cisco Systems (CSCO), QUALCOMM (QCOM), Boeing (BA), Activision Blizzard (ATVI) and Starbucks (SBUX).

Qiagen's stock is owned by many different of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (5.55%), Hardman Johnston Global Advisors LLC (1.77%), First Trust Advisors LP (0.68%), Sycomore Asset Management (0.63%), Russell Investments Group Ltd. (0.22%) and Sector Gamma AS (0.21%).

QGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Assenagon Asset Management S.A., Hardman Johnston Global Advisors LLC, Exane Asset Management, Zurcher Kantonalbank Zurich Cantonalbank, Rhumbline Advisers, Crossmark Global Holdings Inc. and First Bank & Trust.

QGEN stock was purchased by a variety of institutional investors in the last quarter, including Sycomore Asset Management, Massachusetts Financial Services Co. MA, Fisher Asset Management LLC, SG Americas Securities LLC, Sector Gamma AS, Russell Investments Group Ltd., Brinker Capital Inc. and Stephens Investment Management Group LLC.

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of QGEN stock can currently be purchased for approximately $37.49.

Qiagen has a market capitalization of $8.45 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen.

The official website for Qiagen is http://www.qiagen.com/.

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]